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Abstract
Background: Comparative genomic analysis of M. tuberculosis H37Rv and M. bovis BCG have
shown that 16 RDs (Regions of Differences) are deleted in BCG and have shown six deletion
regions in M. tuberculosis H37Rv. RD1, is present in M. tuberculosis but is absent in all M. bovis BCG
sub-strains. A study from Kerala, a south-western coastal state of India aimed to find out
differences in RD1 region showed for the first time the presence of moaA3 gene in majority of their
clinical isolates, that was absent in type strain H37Rv. We attempted to find out such polymorphism
between type strains and the clinical isolates within RD1, targeting moaA3 gene among the clinical
isolates of Tamil Nadu & Pondicherry, south-eastern coastal states of India
Methods: One hundred and sixteen clinical isolates of M. tuberculosis were included in the study.
PCR using RD1DLa and RD1DRa primers was carried out to amplify a 652 bp fragment, encoding
for cfp10 and esat 6 proteins of RD1. A second PCR using primers designed from the surrounding
regions of moaA3 gene was done to confirm the presence of the full Open Reading Frame (ORF)
in clinical isolates.
Results: In M. tuberculosis H37Rv the expected 652 bp band was present. In BCG it was absent as
expected, but a 386 bp fragment was amplified. Around 12/116 (10.3%) of our clinical isolates
showed both 652 and 386 bp fragments. The additional 386 bp amplicon is a part of the moaA3 gene
which codes for molybdopterin cofactor protein A in M. bovis. The second PCR amplified the
flanking sequence of moaA3 and yielded the expected amplicon of 1254 bp in all those 10.3% of
clinical isolates which had the 386 bp fragment. However the earlier study carried out in Kerala,
reported the presence of moaA3 gene in majority (97%) of their clinical isolates.
Conclusion: This finding showed that there was regional variation presenting polymorphism in
moA3 gene, among the strains of M. tuberculosis and further strengthens the speculation of genetic
differences among the strains of Kerala and Tamil Nadu & Pondicherry, the South Indian states
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Background
The passaging of M. tuberculosis H37Rv and M. bovis BCG
over years brought out changes in their genomic and viru-
lence characteristics. Mahairas et al described the genomic
changes in Region of difference 1 (RD1) – a region that is
present in all virulent laboratory and clinical strains of
Mycobacterium bovis and Mycobacterium tuberculosis [1]. The
loss of RD1 in M. bovis BCG, contributes to the attenua-
tion and its reintroduction into an attenuated strain
resulted in a significant increase in virulence [2]. Dele-
tions of RvD1 to RvD5 and TbD1 in H37 Rv are also
reported [3].
A study was planned previously to screen the clinical iso-
lates of M. tuberculosis from Kerala, a south-western costal
state of South India for differences in RD1 region [4].
Amplification using primers that span the ORF coding for
cfp10 and esat 6 has shown to have produced 652 bp in all
M. tuberculosis clinical isolates studied and also an extra
amplicon of 386 bp was amplified in 97% of local field
isolates, but not in M. tuberculosis H37 Rv. Further analysis
revealed that the primer that was made spanning the RD1
region was similar to the portions of the moaA3 gene in
the RvD5 region, which resulted in the amplification of
386 bp fragment. This amplicon spanned the nucleotides
575 to 960 of the moaA3 gene in M. bovis
This prompted us to screen the local isolates from states of
Tamil Nadu and Pondicherry, on the south-eastern
coastal region of South India for the presence of moaA3
gene. Our study revealed a low frequency of moaA3 gene
among Tamil Nadu and Pondicherry clinical isolates com-
pared to higher frequency of moaA3 among the clinical
isolates from the neighbouring Kerala state.
Methods
Mycobacterial Strains
In this study, we included 116 M.tuberculosis non-repeat
clinical isolates from different parts of Tamil Nadu and
Pondicherry. (74 – Obtained from Tuberculosis Research
Centre (TRC), Chennai, Tamil Nadu and 42 from Govern-
ment Chest Disease Hospital, Pondicherry). All the strains
included in this study were isolated in the year 2006 and
the analysis was completed by April 2007. M. tuberculosis
H37RV and M.bovis BCG were used as type strains. All the
strains were identified by biochemical analysis.
Since this study was based on laboratory work carried out
with mycobacterial strains and there was no experimental
work involving human (or) animal, the ethical approval
was not required.
Drug susceptibility Testing (DST)
The in-vitro DST was carried out on solid Lowenstein-
Jensen (LJ) medium using the Minimal Inhibitory Con-
centration (MIC) method/Resistance ratio (RR) method
[5].
Briefly a 3 mm loopful of the bacterial suspension con-
taining approximately 4 mg/ml was used to inoculate
drug-free and drug-containing slopes (32, 64 and 128 mg/
ml). The standard strain, M. tuberculosis H37 Rv was
included in every batch of tests as a check on the inocul-
umn size as well as the drug concentrations in the
medium. The slopes were incubated at 37°C and read at
the end of 28 days. The lowest drug concentration which
inhibited growth (defined as 20 colonies) was taken as the
MIC. RR was defined as the ratio of the MIC of the test iso-
late to the MIC of the reference strain H37Rv.
Extraction of DNA from clinical samples
All the samples were processed for DNA extraction as per
the standard method of Herman et al [6]. Essentially, the
cells were lysed with lysozyme followed by treatment with
proteinase K and sodium dodecyl sulphate. Proteins and
macromolecules were precipitated using NaCl and hexa-
decyltrimethylammonium bromide -NaCl solutions.
Nucleic acids were recovered from aqueous phase after
extraction with chloroform and isoamyl alcohol. DNA
was further precipitated 30 minutes with isopropanol at -
20°C. The pellet was washed with ethanol and later
reconstituted in TE buffer.
PCR amplification of RD1 region
PCR amplification of the RD1 was carried out as described
earlier [4]. Briefly Primers RD1 DLa (For):-5'-AGA TGA
AGA CCG ATG CCG CTA C-3', RD1 DRa (Rev):-5'-CCC
GTG TTT CGC TAT TCT ACG C-3' that can span the RD1
region Rv3874 and Rv3875 coding for cfp 10 and esat 6
were used. After initial denaturation, amplification was
performed in PCR thermocycler (Minicycler-MJ Research)
for 35 cycles at 95°C/40 sec, 64°C/1 min, 72°C/1 min
followed by a final extension at 72°C/5 min. It was
expected to yield a 652 bp product and also 386 bp prod-
ucts if moaA3 was present in the test isolates, only 652 bp
product in M. tuberculosis H37Rv and only 386 bp prod-
ucts in M. bovis BCG.
To identify the flanking sequence of the 386 bp another
set of primers were used (moaFP – 5'-CCC ATC GTG GTC
GTT CAC C-3' and moaRP – 5'-CGA TGG CAG CGG TTT
ACA G-3') to amplify a 1254 bp product, with the same
conditions as done for the above amplification.
PCR amplification for IS6110
Amplification of DNA for IS6110 was performed with
primers IS-F – 5'-CCTGCGAGCGTA GG CGTCGG-3'and
IS-R – 5'CTCGTCCAGCGCCGCTTCGG-3', to amplify 123
bp fragment of insertion element IS6110 of M. tuberculosis
complex as reported earlier [7]. Briefly PCR was carriedBMC Infectious Diseases 2009, 9:114 http://www.biomedcentral.com/1471-2334/9/114
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out in 50 μl volume, using 200 μM dNTPs, 20 pM of each
primer and 1 U of Taq polymerase, followed by template.
Conditions followed were initial denaturation at 94°C for
4 minutes, followed by 35 cycles at 90°C for 1 minute,
60°C for 1 minute, and 72°C for 1 minute, and a final
extension at 72°C for 10 minutes.
Results
Screening of RD1
The PCR primers designed to amplify regions within RD1
to find out the polymorphism between the type strain and
the clinical isolates amplified the expected 652 bp frag-
ment (comprising of Rv 3874 and Rv 3875, coding for
cfp10 and esat 6) in M. tuberculosis H37Rv. In M.bovis BCG,
the 652 bp was absent as expected, but a 386 bp fragment
was amplified. All the 116 clinical isolates showed 652 bp
products. However in 8 out of 74 (10.8%) of Tamil Nadu
isolates and 4 out of 42 (9.5%) of Pondicherry isolates
showed both 652 and 386 bp fragments (Figure 1). Thus,
12 out of the 116(10.3%) samples showed the extra
amplicon of 386 bp. (Table 1)
The second PCR using primers designed from the sur-
rounding region of moaA3 gene done to confirm the pres-
ence of the full ORF in clinical isolates, amplified the
expected 1254 bp in all the clinical isolates which showed
the extra 386 bp amplicon. (Figure 2) (Table 2)
As our isolates showed a lower frequency of moaA3 gene,
we checked the possibility of false negativity by including
50 DNA templates from those isolates which were posi-
tive for 652 bp of RD1, but found negative for 386 bp
extra amplicon and ran second PCR to amplify the flank-
ing sequences. None of these templates were positive for
flanking sequence. Thus, the remote possibility of false
negativity as a cause for lower frequency of moaA3 gene
among our isolates was ruled out.
Screening of IS 6110
PCR for IS6110 showed the 123 bp fragment in all 116
(100%) clinical isolates. (Table 1)
Correlation with drug susceptibility results
For 58 TRC clinical isolates, drug susceptibility result was
available. Resistance to Streptomycin (S), Isoniazid (H),
Rifampicin(R), and Ethambutol (E) were 33%, 14%, 0%
and 25%, among moaA3 positive samples where as among
moaA3 negative samples were 29%, 34%, 20% and 14%
respectively. Multi Drug Resistance (MDR) was observed
in 18% (9/46) of samples negative for moaA3, where as no
MDR was observed among moaA3 positive sample. How-
ever, as most of the samples tested were moaA3 negative
and only few samples were positive the statistical signifi-
cance could not be drawn for want of adequate sample
size in both the comparable groups.
Discussion
Studies with subtractive hybridization and microarrays
have identified 16 regions present in M. tuberculosis
H37Rv but are absent in M. bovis BCG [1,8]. Further dele-
tions of RvD1 to RvD5 and TbD1 genes in H37Rv are also
reported [3]. RD1 region comprises of nine genes (Rv3871
to Rv3879c) and spans a 9.5-kb region. In M. bovis BCG,
RD1 deletion completely removes seven genes (Rv3872 to
Rv3878) and truncates two others (Rv3871 and Rv3879c)
[9].
Of the nine genes predicted within the 9.5 kb RD1 region,
those coding for cfp 10 (Rv3874) and esat 6 (Rv3875) are
immunogenic and RD1 deletion mutants of M. tuberculo-
sis have been found to be less virulent [9]
Thus, generation of deletion of genes appear to be a major
mechanism for creating genetic diversity.
Based on this, a study from Kerala was carried-out to
screen for differences in the RD1 region. Amplification
using primers that span the ORF coding for cfp10 and esat
6 was expected to give a 652 bp PCR product. But the PCR
results revealed an extra amplicon of 386 bp in 97% of the
clinical isolates screened. Further characterization by
sequencing and homology search indicated that this
region is a part of the moaA3  gene which encodes for
molybdopterin cofactor protein A in M.bovis. The PCR
primer that was made spanning the RD1 region was
shown to be similar to portions of the moaA3 (MT3427)
gene in the RvD5 region in clinical isolates and also in
CDC1551 which resulted in the amplification of the 386
bp fragment. This amplicon spanned the nucleotides 575
to 960 of the moaA3 gene (MT 3355) in M. bovis [4]
With this background, we searched for the presence of
moaA3  gene among the clinical isolates collected from
PCR for amplification of cfp 10 and esat 6 of RD1 Figure 1
PCR for amplification of cfp 10 and esat 6 of RD1. 
Lane-1 – Molecular weight marker (100 bp ladder). Lane-2 – 
M. tuberculosis H37Rv, showing only 652 bp (RD1). Lane-3 – 
M. bovis BCG showing only 386 bp. Lane-4 & 5 – Clinical iso-
lates showing 652 bp & 386 bp extra amplicon (moaA3). 
Lane-6 to 11 – Clinical isolates showing 652 bp only. Lane12 
– Negative control.BMC Infectious Diseases 2009, 9:114 http://www.biomedcentral.com/1471-2334/9/114
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Tamil Nadu and Pondicherry. Our search showed pres-
ence of 652 bp of cfp10 and esat 6 of RD1 region in all the
116 clinical isolates screened but only a limited number
of 12/116 (10.3%) clinical isolates showed the presence
of 386 bp amplicon of moaA3. Amplification of flanking
sequence of 386 bp moaA3 showed the expected 1254 bp
product in among all the isolates showed the extra 386 bp
amplicon. Thus, in contrast to Kerala study, only in lim-
ited proportion of our isolates moaA3 was amplified using
the designed primer.
Although Rao et al, [10] reported total absence of RD1
region in clinical isolates, in a study from Hyderabad,
Andhrapradesh (a south eastern coastal state) all our clin-
ical isolates showed the presence of RD1 (cfp 10 and east
6) region. In fact, few isolates we obtained from Hydera-
bad were found positive for RD1 region in all the isolates
(data not shown). This is in concurrence with other
reports [11,4].
In H37Rv, the moaA3 amplicon was shown to be absent.
The RvD5 region from which the amplicon was generated
is an IS6110 mediated deletion in the type strain H37Rv
[3]. IS6110 is a powerful genetic marker for strain differ-
entiation [12]. In general low/no copies of IS6110 were
implicated among south-east Asian strains, including
India [13-15].
However, a closer scrutiny at the frequency of no/low cop-
ies of IS6110 reveals that they are commoner among Ker-
ala strains than those from Tamil Nadu. An analysis from
Kerala [16] reported about 24% of no copies and 39% of
single copy of IS6110 in their isolates. Thus, around
62.5% of (50 out of 80) strains analyzed were not type-
able by IS6110 based finger printing. This reported to be
higher than the small numbers of IS6110 – deficient
strains -1%–4% reported in Tamil Nadu [17,18]. It is
appropriate to underscore that all our isolates screened for
IS6110 by PCR were found positive.
Adding to this genetic variations, our finding of low fre-
quency of 10.3% of moaA3 gene among Tamil Nadu and
Pondicherry isolates compared to the higher proportion
of 97% among Kerala isolates, further strengthens the
speculation of genetic variation among the strains of Ker-
ala and Tamil Nadu & Pondicherry, the South Indian
states.
Further in screening of different genes of RD1 region
among clinical isolates from Kerala and Western and
Northern India, Rv 3871 and Rv 3872 (part of RD1
region) was reported as high as 98% in Kerala isolates,
where as only 30% was reported in the other isolates
screened [11].
This further emphasizes the need to carry out systematic
molecular epidemiological studies in these endemic areas
to explore any other genetic variations. Further the role of
IS6110 or any other insertion sequences or mobile genetic
elements in the genetic variation may also be investigated.
Conclusion
Our attempt to screen for moaA3 gene among the clinical
isolates of Tamil Nadu and Pondicherry revealed a low
frequency of moaA3 gene compared to a high frequency of
moaA3 gene among Kerala isolates. This finding showed a
regional variation presenting polymorphism in moA3
gene, among the strains of M.tuberculosis  and further
strengthens the speculation of genetic variations among
Table 1: PCR for amplification of cfp10 and esat 6 of RD1
Source of samples No. of samples investigated No. of samples positive for 
IS6110
No. of samples positive for 
652 bp
No. of samples positive for 652 
bp + 386 bp
Tamil Nadu 74 74 (100%) 74 (100%) 08 (10.8%)
Pondicherry 42 42 (100%) 42 (100%) 04 (9.5%)
Total 116 116 (100%) 116 (100%) 12 (10.3%)
652 bp – product found in M. tuberculosis H37Rv; 386 bp – product found in M. bovis BCG
PCR for amplification of flanking sequence of 386 bp of  moaA3 gene Figure 2
PCR for amplification of flanking sequence of 386 bp 
of moaA3 gene. Lane-1 – Molecular weight marker (500 bp 
ladder). Lane-2 to 7 – Clinical isolates which were positive 
for 386 bp extra amplicon, showing 1254 bp of flanking 
sequence. Lane-8 – Negative control.BMC Infectious Diseases 2009, 9:114 http://www.biomedcentral.com/1471-2334/9/114
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the strains of Kerala and Tamil Nadu & Pondicherry, the
neighbouring South Indian states.
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Table 2: PCR for amplification of Flanking sequence of 386 bp of moaA3 gene
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